

Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/F068A8D61FD0EN.html>

Date: March 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: F068A8D61FD0EN

Abstracts

Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 4, 9, 1 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Familial Adenomatous

Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Familial Adenomatous Polyposis - Overview
- Familial Adenomatous Polyposis - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Familial Adenomatous Polyposis - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
 - ADT Pharmaceuticals Inc
 - Cancer Prevention Pharmaceuticals Inc
 - Cellix Bio Pvt Ltd
 - DNALite Therapeutics Inc
 - Eloxx Pharmaceuticals Inc
 - Emtora Biosciences
 - FunPep Co Ltd
 - Jiangsu Hengrui Medicine Co Ltd
 - Johnson & Johnson
 - KD Pharma Group SA
 - Recursion Pharmaceuticals Inc
 - SanaRx Biotherapeutics Inc
 - Stemsynergy Therapeutics Inc
 - Sumitomo Dainippon Pharma Co Ltd
 - TherapyX Inc
 - Thetis Pharmaceuticals LLC
- Familial Adenomatous Polyposis - Drug Profiles
 - (eflornithine hydrochloride + sulindac) - Drug Profile
 - Product Description
 - Mechanism Of Action
 - History of Events
 - CLXONC-575 - Drug Profile
 - Product Description
 - Mechanism Of Action

FAPXIL SR - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Familial Adenomatous Polyposis - Drug Profile

Product Description

Mechanism Of Action

guselkumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

icosapent ethyl - Drug Profile

Product Description

Mechanism Of Action

History of Events

interleukin-10 SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

lorpucitinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

magnesium lysinate bis eicosapentaenoate - Drug Profile

Product Description

Mechanism Of Action

History of Events

ombipepimut-s - Drug Profile

Product Description

Mechanism Of Action

History of Events

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

History of Events

REC-4881 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-201 - Drug Profile

Product Description
Mechanism Of Action
SHR-1020 - Drug Profile
Product Description
Mechanism Of Action
sirolimus - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PDE10 for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Synthetic peptide for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZKN-013 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Familial Adenomatous Polyposis - Dormant Projects
Familial Adenomatous Polyposis - Discontinued Products
Familial Adenomatous Polyposis - Product Development Milestones
Featured News & Press Releases
Oct 12, 2021: Flynpovi: Withdrawal of the marketing authorisation application
Sep 29, 2021: Recursion is granted orphan drug designation for REC-4881 for the potential treatment of familial adenomatous polyposis
Jul 23, 2021: Cancer Prevention Pharmaceuticals has requested a re-examination of EMA's June 2021 opinion on Flynpovi
Jun 25, 2021: CHMP adopted a negative opinion on the marketing authorisation application for Flynpovi
Sep 11, 2020: Cancer Prevention Pharmaceuticals Announces NEJM publication of landmark phase 3 clinical trial for treatment of familial adenomatous polyposis
Jun 29, 2020: Cancer Prevention Pharmaceuticals submits New Drug Application to the FDA for CPP-1X/sul for treatment of familial adenomatous polyposis

Jun 18, 2020: Cancer Prevention Pharmaceuticals submits EU marketing authorization application for CPP-1X/sul for treatment of familial adenomatous polyposis

Apr 15, 2020: KD Pharma and SLA Pharma to study EPAspire for Covid-19

Nov 17, 2019: National Institute of Diabetes and Digestive and Kidney Diseases awards \$2,073,687 SBIR fasttrack grant to Therapyx

Aug 26, 2019: Emtora Biosciences awarded \$3 million CPRIT grant to study efficacy of eRapa in familial adenomatous polyposis

Aug 01, 2019: SLA Pharma announces meeting with the FDA in October 2019 for ALFA

Jun 20, 2019: Cancer Prevention Pharmaceuticals (CPP) reports FAP phase 3 clinical trial results at Digestive Disease Week Conference

May 07, 2019: Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt announce results from pivotal phase 3 trial of CPP-1X/Sulindac in patients with familial adenomatous polyposis

Apr 15, 2019: MorphoSys announces that its licensee Janssen has expanded clinical development of Guselkumab (Tremfya) into familial adenomatous polyposis

Feb 26, 2019: Rapamycin Holdings rebrands to Emtora Biosciences as new leadership focuses company on next steps

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Familial Adenomatous Polyposis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Familial Adenomatous Polyposis - Pipeline by ADT Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by DNAlite Therapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Eloxx Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Emtora Biosciences, 2022
Familial Adenomatous Polyposis - Pipeline by FunPep Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by Johnson & Johnson, 2022
Familial Adenomatous Polyposis - Pipeline by KD Pharma Group SA, 2022
Familial Adenomatous Polyposis - Pipeline by Recursion Pharmaceuticals Inc, 2022
Familial Adenomatous Polyposis - Pipeline by SanaRx Biotherapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Stemsynergy Therapeutics Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Familial Adenomatous Polyposis - Pipeline by TherapyX Inc, 2022
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, 2022
Familial Adenomatous Polyposis - Dormant Projects, 2022
Familial Adenomatous Polyposis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Familial Adenomatous Polyposis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/F068A8D61FD0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F068A8D61FD0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

